Cameron Santoro is an associate editor for The American Journal of Managed Care® (AJMC®), AJMC.com, and The Center for Biosimilars®.
Teledermatology Benefits Underserved Populations, Reduces Physician Burnout
Elizabeth Jones, MD, FAAD, Thomas Jefferson University Hospitals, advocates for teledermatology as a vital tool to enhance health care equity by improving access for underserved populations and reducing physician burnout.
Baricitinib Shows Promise for Pediatric Alopecia in BRAVE-AA-PEDS Study
Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198), emphasizing the balance between treatment efficacy and safety.
Tailoring Atopic Dermatitis Treatment and the Safety of Topical Therapies, Ruxolitinib
Lawrence Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the importance of shared decision-making in atopic dermatitis treatment, emphasizing personalized care based on patient history and the favorable long-term safety profile of topical ruxolitinib.
Addressing Social Determinants of Health Improves Dermatologic Care in Underserved Populations
Rebecca Vasquez, MD, FAAD, University of Texas Southwestern Medical Center, emphasizes the necessity of addressing social determinants to improve dermatological care and access for underserved populations.
Trump’s Immigration Crackdown Fuels Health Crisis: Detention, Depression, Deportation, and Disease
Strict changes to immigration policies nationwide create a public health crisis in overcrowded detention centers, draining taxpayer dollars and diminishing undocumented immigrants' contributions to subsidies.
An Elevated Member Experience, More Education, and Martha Stewart at the AAD 2025 Annual Meeting
Seemal R Desai, MD, FAAD, president of the American Academy of Dermatology (AAD), emphasized his commitment to enhancing the upcoming 2025 annual meeting by introducing new events and expanding educational offerings to better serve and engage members.
ASCO GU Posters Address Cost-Effectiveness, Implementation Barriers for New mUC Treatments
Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into practice due to high costs and a lack of targeted initiatives to aid health care providers with integration.
Bimekizumab-bkzx Expands Treatment Options for Inflammatory Conditions
Jeffrey Stark, MD, vice president and head of medical immunology at UCB, discusses tailored dosing of bimekizumab-bkzx (Bimzelx) for various inflammatory conditions, highlighting its 5 FDA approvals and the remaining challenges.
The Uncertain Road Ahead for Health Care After DEI Rollbacks
The removal of FDA guidance on clinical trial diversity and related anti–diversity, equity, and inclusion (DEI) actions may hinder progress toward equitable health care, impacting workforce diversity, patient outcomes, and research.
Addressing Cancer Treatment Costs With Patient-Provider Communication
Clayton Irvine, PharmD, MBA, MS, senior manager of oncology care at Mayo Clinic, emphasizes the need for health care providers to balance quality patient care with rising costs by openly discussing financial implications with patients and educating themselves on cost-effective treatments.
New Model Predicts Stroke Severity and Improves Functional Independence
A new predictive model developed by Ochsner Health helps clinicians make real-time decisions for patients who had a stroke undergoing urgent carotid intervention, improving chances of regaining functional independence.
Optimizing Oncology Drug Use While Mitigating Shortages
Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at Mayo Clinic, suggests that medical providers can reduce patient and system costs by optimizing the use of generics and biosimilars, which offer lower costs without compromising safety and efficacy.
Biosimilar Market Share: Growth and Price Trends in Q1 2025
Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine biosimilars have grown more slowly.